OsteoStrong®, the global leader in osteogenic loading technology for bone health, proudly announces that a groundbreaking study on its proprietary system has been accepted for publication in The ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in postmenopausal women ...